| human | Q5 |
| P496 | ORCID iD | 0000-0003-1328-1959 |
| P69 | educated at | University of Cambridge | Q35794 |
| Jagiellonian University | Q189441 | ||
| P734 | family name | Staniszewska | Q111677477 |
| Staniszewska | Q111677477 | ||
| Staniszewska | Q111677477 | ||
| P735 | given name | Anna | Q666578 |
| Anna | Q666578 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q52430499 | Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions. |
| Q43053542 | CD70-driven chronic immune activation is protective against atherosclerosis |
| Q56892381 | Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity |
| Q52730266 | Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. |
| Q47709826 | Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors |
| Q91518680 | Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery |
| Q60931648 | PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8 T-cell activity |
| Q112157761 | Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity |
| Q48530601 | Stat3 controls lysosomal-mediated cell death in vivo |
| Q34534230 | Stat3 is required to maintain the full differentiation potential of mammary stem cells and the proliferative potential of mammary luminal progenitors |
| Q38700328 | Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. |
| Q41908057 | VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells |
Search more.